Using smart nanoparticles to deliver a natural cancer-fighting drug for metastatic colorectal cancer.
Official title: "SMART" nanoparticle delivery of veratridine overcomes clinical challenges in metastatic colorectal cancer.
Funded at University of South Dakota · NIH-11077358 · Data updated 2026-11-12
This study is testing a new way to deliver a natural anti-cancer drug directly to metastatic colorectal cancer cells using tiny particles, which could make the treatment work better and cause fewer side effects for patients with advanced CRC.
Quick facts
| Grant type | R03 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of South Dakota NIH-funded |
| Lab location | 1 site (Vermillion, United States) |
| Project start | May 1, 2024 |
| Project end | April 30, 2026 |
| Funding year | 2025 |
| Award (this year) | $74,750 |
| NIH project number | 5R03CA290549-02 |
| Project ID | NIH-11077358 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with metastatic colorectal cancer who have not responded well to conventional treatments.
✕Less likely to help
Patients with early-stage colorectal cancer or those whose cancer has not metastasized may not benefit from this research.
What this research studies
This research focuses on developing innovative nanoparticles that can deliver a natural anti-cancer drug, veratridine, directly to metastatic colorectal cancer (CRC) cells. The approach aims to enhance the effectiveness of the treatment while minimizing side effects on healthy cells. By utilizing smart technology, these nanoparticles will release the drug specifically at tumor sites, which could improve treatment outcomes for patients with advanced CRC. The research involves both laboratory and animal testing to evaluate the effectiveness and safety of this targeted delivery method.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatment options for patients with metastatic colorectal cancer.
How similar studies have gone: Previous research has shown promise in using targeted nanoparticle delivery systems for cancer treatment, indicating potential success for this novel approach.
Where this research is happening
-
University of South Dakota
Vermillion, United States Active
Researchers
- Principal investigator: Rezvani, Khosrow Samuel — University of South Dakota
- Study coordinator: Rezvani, Khosrow Samuel
Related research
Other NIH-funded projects on the same topics.
-
Population-based view of patient-reported outcomes in adults with metastatic colorectal cancer
This grant funds a long-term study to understand experiences and quality of life for adults living with metastatic colorectal cancer.
-
Nanodelivery of FP polymers to improve treatment of metastatic colorectal cancer
A new nanoscale therapy called CF10 is being developed to deliver a chemotherapy drug more directly to metastatic colorectal cancer, aiming for better tumor targeting and fewer side effects.
-
How metastatic colorectal cancer weakens muscles and bones
This research looks at how metastatic colorectal cancer and a hormone called FGF21 cause muscle and bone wasting in people with advanced colorectal cancer.
-
Nanoscale polymers delivering patient-specific cancer vaccines for metastatic colorectal cancer
A new therapy uses tiny, designer particles to carry patient-specific cancer antigens to tumors in people with advanced colorectal cancer.
-
Targeted nanoparticles combining chemotherapy and immune stimulation for advanced colon cancer
Targeted nanoparticles that deliver a two-drug chemotherapy combo plus immune-activating components are being developed to help people with metastatic colorectal (colon) cancer that usually does not respond to current immunotherapy.
-
Symptoms and quality of life in adults living with metastatic colorectal cancer
Researchers will follow adults with metastatic colorectal cancer over time to learn what symptoms and quality-of-life issues they experience during treatment and survivorship.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.